Sterling firms against dollar as markets look to BoE rate guidance
The BoE is widely expected to cut its key interest rate to 4% from 4.25% on Thursday and to lower it once more before the end of the year, despite consumer price inflation rising to close to double the central bank's 2% target in June.
Traders priced in over a 90% chance of an easing move this week and 86 bps of rate cuts by December 2026.
The pound was up 0.05% at $1.3290 against the dollar .
The greenback rose against the euro and the yen, but remained within striking distance of Friday's lows.
'Given the stagflationary character of the data, we expect 'gradual and careful' to stay as the main forward guidance, with a highly uncertain vote split,' said Citi.
'We expect this situation to remain until the autumn budget, after which contractionary tax increases, in our base case, should pave the way for sequential rate cuts.'
Britain borrowed more than expected in June, adding to speculation about the need for new tax hikes by finance minister Rachel Reeves later this year.
'We suspect that it (the BoE) will (maintain its gradual and careful rate guidance), although any change here would almost certainly be greeted by a bout of pound weakness,' said Enrique Diaz-Alvarez, chief economist at Ebury.
The British currency was last up 0.3% at 86.85 pence per euro. It fell to 87.69 pence last week, its weakest against the single currency since May 2023.
Yields on UK gilts snapped a 5-day losing streak on Tuesday, with the 10-year up 2.5 bps at 4.53%.
'Risks are two-sided: a faster or more pronounced loosening of the labour market could warrant cumulative or larger cuts, whereas sticky underlying (services) inflation and only gradual signs of labour-market slack could extend the pause between cuts beyond current expectations,' said Nikolay Markov economist at Pictet Asset Management.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
31 minutes ago
- The Sun
15 reasons why the Ford Transit is the GOAT of the van world – from transporting rock bands, elephants and even ROYALS
WE could argue all night about who is the GOAT. 15 15 15 But when it comes to vehicles, it's not even a debate. G reatest O f A ll T ransit. The humble Ford Transit has been Britain's best-selling van since day one - August 9, 1965. That's like Liverpool winning the Prem for 60 years on the bounce. Everyone else might as well give up and go home. To celebrate Transit's 60th, we've peppered today's column with quirky facts, as well as hearing from owners with a cherished van from each decade. Ford's famous Backbone Of Britain telly ad from the Eighties was genius marketing. Yet also 100 per cent true. Transit keeps this country ticking. Everything we see and touch was transported in a van. 15 15 One reason Transit is successful is that Ford engineers sit with owners to find ways of making the next model even more useful. Like the bloke who shoved a lump of wood through the bottom of the steering wheel to make a lunch table. The latest Transit Custom has a tilt-up steering wheel with a tray for his quinoa tuna salad. Bosh. Ford's insane V8 1971 Transit Supervan Retired builder Peter Lee, founder of the Transit Van Club, said: 'Transit is like a forklift with two doors. "Built to work. They're good honest vans that will do the job.' The OG and still the best. 3 MILLION UK sales and counting. Always available in white. 15 15 15 15 15 15
The Guardian
an hour ago
- The Guardian
Sales of Novo Nordisk's diabetes drugs including Ozempic slow sharply
Sales of Novo Nordisk's injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus. The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe's most valuable company, has lost nearly $100bn (£75bn) in market value since cutting its full-year sales forecast last week, when its share price slid 30% in its worst week in more than two decades. It fell a further 3% on Wednesday. On Wednesday, Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and appetite – grew by 8% in the first half of the year, down from 21% last year. Sales of obesity drugs including Wegovy increased by 56%, taking total sales 16% higher to 155bn Danish kroner (£18bn). Profit before tax climbed by 24% to 70.8bn kroner. The company has lost market share to its US rival Eli Lilly's Mounjaro, which studies have shown to be more effective, as well as cheaper versions made by generic drugmakers. It has also been hit by 'compounding' in the US, where pharmacies make up medications from ingredients, even though the US regulator declared an end to the practice recently. Novo Nordisk's outgoing chief executive, Lars Fruergaard Jørgensen, said that the copycat market had 'equal size to our business' and that compounded versions of Wegovy were sold at a 'much lower price point'. Its finance chief, Karsten Munk Knudsen, said the company was pursuing various strategies, including lawsuits against compounding pharmacies and expanding its US direct-to-consumer platform, NovoCare, launched in March. The company might also pursue 'cash sales' directly to patients elsewhere. Jørgensen said Novo Nordisk was taking measures to 'sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth'. He said it would probably not be able to avoid layoffs, but that no decision had been made. He said it would be up to Maziar Mike Doustdar, who takes over as CEO on Thursday, to make such a decision. The company is now expecting sales growth of between 8% and 14% at constant exchange rates in 2025, down sharply from its previous estimate of 13% to 21%. Novo Nordisk also disclosed that it had ditched several weight-loss drugs in development, including one that has just completed an intermediate (phase II) clinical study, 'due to portfolio considerations'. The company faces a class action lawsuit in the US from investors, who claim that it misled them with optimistic growth forecasts in the lucrative weight loss market. The UBS analyst Matthew Weston said: 'We expect GLP-1 compounders to remain in the US, which limits cash-pay uptake and leaves an uncertain outlook for US Wegovy. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion 'President Trump's proposal to reimburse GLP-1 obesity in Medicare could add significant volume uplift, but most-favoured-nation demands to offer US cash sales at European prices could significantly reduce value.' Derren Nathan, the head of equity research at Hargreaves Lansdown, said: 'Tariffs and drug pricing policy are another threat Mike Doustdar will need to tackle head-on if one of Denmark's greatest success stories is to regain its crown as Europe's most valuable company. 'The 15% blanket rate on EU imports is not necessarily the end of the story as Donald Trump dangles the prospect of levies of up to 250% on pharmaceutical imports under a separate section 232 investigation.'
Telegraph
an hour ago
- Telegraph
A long-term plan is needed to get the country out of its financial hole
SIR – Whether by raising income tax rates, a wealth tax or through less overt measures, the Government will try to extract more money from the people that it serves ('Reeves facing £50bn black hole as tax pressure mounts ', report, August 6). However, such measures risk being self-defeating. Those who are unable or unwilling to leave the country will bear the brunt of the tax rises. That includes standard and higher-rate taxpayers. Every pound the Government extracts from their bank accounts is a pound that cannot be spent on businesses that provide goods and services. Thus, businesses will take another hit which, in turn, will reduce their tax payments. Since the failure of the Truss administration, there has been no long-term plan to get the country out of its financial hole. Eventually, there will have to be one and it will likely involve curbing the insatiable appetite of government to control and spend. When such a plan sees the light of day we may be surprised at the boost it gives to confidence and investment. David Porter Plymouth, Devon SIR – Labour dug itself a financial hole when it pledged not to increase National Insurance (NI), VAT or income tax rates. Instead of imposing VAT on private schools and possibly even on private health, a simple 1 or 2 per cent rise on NI and/or the basic rate of income tax would have solved the Chancellor's problems. Now she is having to cast her net wider – and creating more problems as a result. John Tilsiter Radlett, Hertfordshire SIR – Taxing jobs and taxing capital is not going to result in economic growth. Is it too much to expect a former Bank of England economist to grasp this? Patrick Loxdale Aberystwyth, Ceredigion SIR – There is a limit to which any economy can be taxed. The UK is at that limit. The British public understands this. It is plain that public sector expenditure must be cut to balance the books. Given the Government throws billions around like confetti – on the Chagos Islands, the immigration fiasco, welfare, public sector pay rises, excessive numbers of civil servants – there is much low-hanging fruit. The economy is being badly managed as never before. Enough is enough. Please can we have some economic sanity. Stuart Moore Bramham, West Yorkshire SIR – Having continually criticised the Conservatives for the last 12 months for creating a £22bn black hole in the public finances, I trust Labour will now be constantly criticising itself for doubling the deficit. Paul Webster Dyserth, Denbighshire
